Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

COVID-19

Free Subscription Articles published in Life Sci Retrieve available abstracts of 155 articles: HTML format

Single Articles

February 2024
1. YOUSEF M, Rob M, Varghese S, Rao S, et al
   The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review.
   Life Sci. 2024;342:122535.
   PubMed     Abstract available
   
   
   December 2023
2. PORIA R, Kala D, Nagraik R, Dhir Y, et al
   Vaccine development: Current trends and technologies.
   Life Sci. 2023 Dec 7:122331. doi: 10.1016/j.lfs.2023.122331.
   PubMed     Abstract available
   
   
   November 2023
3. MORA-RODRIGUEZ JM, Sanchez BG, Bort A, Diaz-Yuste A, et al
   Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
   Life Sci. 2023;336:122292.
   PubMed     Abstract available
   
   
   
4. ZEYADA MS, Eraky SM, El-Shishtawy MM
   Trigonelline mitigates bleomycin-induced pulmonary inflammation and fibrosis: Insight into NLRP3 inflammasome and SPHK1/S1P/Hippo signaling modulation.
   Life Sci. 2023 Nov 17:122272. doi: 10.1016/j.lfs.2023.122272.
   PubMed     Abstract available
   
   
   October 2023
5. PETPIROON N, Netkueakul W, Sukrak K, Wang C, et al
   Development of lung tissue models and their applications.
   Life Sci. 2023 Oct 24:122208. doi: 10.1016/j.lfs.2023.122208.
   PubMed     Abstract available
   
   
   
6. KRASAEWES K, Chaiwarith R, Chattipakorn N, Chattipakorn SC, et al
   Profiles of gut microbiota associated with clinical outcomes in patients with different stages of SARS-CoV-2 infection.
   Life Sci. 2023;332:122136.
   PubMed     Abstract available
   
   
   September 2023
7. ZHONG HL, Li PZ, Li D, Guan CX, et al
   The role of vasoactive intestinal peptide in pulmonary diseases.
   Life Sci. 2023 Sep 22:122121. doi: 10.1016/j.lfs.2023.122121.
   PubMed     Abstract available
   
   
   
8. ROSA CP, Belo TCA, Santos NCM, Silva EN, et al
   Reactive oxygen species trigger inflammasome activation after intracellular microbial interaction.
   Life Sci. 2023;331:122076.
   PubMed     Abstract available
   
   
   July 2023
9. LU X, Mao T, Dai Y, Zhu L, et al
   Azithromycin exposure during pregnancy disturbs the fetal development and its characteristic of multi-organ toxicity.
   Life Sci. 2023;329:121985.
   PubMed     Abstract available
   
   
   
10. ISAZADEH A, Heris JA, Shahabi P, Mohammadinasab R, et al
    Pattern-recognition receptors (PRRs) in SARS-CoV-2.
    Life Sci. 2023;329:121940.
    PubMed     Abstract available
    
    
    June 2023
11. YAZDANPARAST S, Bakhtiyaridovvombaygi M, Mikanik F, Ahmadi R, et al
    Spotlight on contributory role of host immunogenetic profiling in SARS-CoV-2 infection: Susceptibility, severity, mortality, and vaccine effectiveness.
    Life Sci. 2023 Jun 30:121907. doi: 10.1016/j.lfs.2023.121907.
    PubMed     Abstract available
    
    
    May 2023
12. QUEIROZ-JUNIOR CM, Santos ACPM, Goncalves MR, Brito CB, et al
    Acute coronavirus infection triggers a TNF-dependent osteoporotic phenotype in mice.
    Life Sci. 2023 May 2:121750. doi: 10.1016/j.lfs.2023.121750.
    PubMed     Abstract available
    
    
    March 2023
13. DELDADEH N, Haghighat S, Omidi Z, Sarrami-Foroushani R, et al
    Anti-cancer effect of COVID-19 vaccines in 4T1 mice models.
    Life Sci. 2023 Mar 10:121569. doi: 10.1016/j.lfs.2023.121569.
    PubMed     Abstract available
    
    
    February 2023
14. SHER EK, Cosovic A, Dzidic-Krivic A, Farhat EK, et al
    Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases.
    Life Sci. 2023 Feb 27:121531. doi: 10.1016/j.lfs.2023.121531.
    PubMed     Abstract available
    
    
    
15. GHORBANINEJAD M, Asadzadeh-Aghdaei H, Baharvand H, Meyfour A, et al
    Intestinal organoids: A versatile platform for modeling gastrointestinal diseases and monitoring epigenetic alterations.
    Life Sci. 2023 Feb 27:121506. doi: 10.1016/j.lfs.2023.121506.
    PubMed     Abstract available
    
    
    
16. EHTESHAMINIA Y, Jalali SF, Jadidi-Niaragh F, Enderami SE, et al
    Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment.
    Life Sci. 2023 Feb 23:121525. doi: 10.1016/j.lfs.2023.121525.
    PubMed     Abstract available
    
    
    January 2023
17. SAXENA R, Sharma P, Kumar S, Agrawal N, et al
    Modulation of mitochondria by viral proteins.
    Life Sci. 2023;313:121271.
    PubMed     Abstract available
    
    
    
18. LIN F, Lin X, Fu B, Xiong Y, et al
    Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development.
    Life Sci. 2023;315:121374.
    PubMed     Abstract available
    
    
    December 2022
19. HUSSEIN RM, Arafa EA, Raheem SA, Mohamed WR, et al
    Thymol protects against bleomycin-induced pulmonary fibrosis via abrogation of oxidative stress, inflammation, and modulation of miR-29a/TGF-beta and PI3K/Akt signaling in mice.
    Life Sci. 2022 Dec 19:121256. doi: 10.1016/j.lfs.2022.121256.
    PubMed     Abstract available
    
    
    October 2022
20. ANTAR SA, Saleh MA, Al-Karmalawy AA
    Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2.
    Life Sci. 2022;309:121048.
    PubMed     Abstract available
    
    
    September 2022
21. ALEKSOVA A, Fluca AL, Gagno G, Pierri A, et al
    Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality.
    Life Sci. 2022 Sep 29:121018. doi: 10.1016/j.lfs.2022.121018.
    PubMed     Abstract available
    
    
    
22. HSU PC, Shahed-Al-Mahmud M
    SARS-CoV-2 mediated neurological disorders in COVID-19: Measuring the pathophysiology and immune response.
    Life Sci. 2022 Sep 20:120981. doi: 10.1016/j.lfs.2022.120981.
    PubMed     Abstract available
    
    
    
23. BARTOLOMEO CS, Lemes RMR, Morais RL, Pereria GC, et al
    SARS-CoV-2 infection and replication kinetics in different human cell types: The role of autophagy, cellular metabolism and ACE2 expression.
    Life Sci. 2022 Sep 5:120930. doi: 10.1016/j.lfs.2022.120930.
    PubMed     Abstract available
    
    
    August 2022
24. SHARIF-ASKARI FS, Hafezi S, Sharif-Askari NS, Alsayed HAH, et al
    Vitamin D modulates systemic inflammation in patients with severe COVID-19.
    Life Sci. 2022 Aug 23:120909. doi: 10.1016/j.lfs.2022.120909.
    PubMed     Abstract available
    
    
    
25. HOSSEINZADEH A, Bagherifard A, Koosha F, Amiri S, et al
    Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19.
    Life Sci. 2022;307:120866.
    PubMed     Abstract available
    
    
    July 2022
26. ALI MA, El-Tahan RA, Kamel MA, Matar NA, et al
    The diabetogenic effects of chronic supplementation of vitamin C or E in rats: Interplay between liver and adipose tissues transcriptional machinery of lipid metabolism.
    Life Sci. 2022 Jul 18:120812. doi: 10.1016/j.lfs.2022.120812.
    PubMed     Abstract available
    
    
    
27. MALEKINEJAD Z, Baghbanzadeh A, Nakhlband A, Baradaran B, et al
    Recent clinical findings on the role of kinase inhibitors in COVID-19 management.
    Life Sci. 2022 Jul 13:120809. doi: 10.1016/j.lfs.2022.120809.
    PubMed     Abstract available
    
    
    
28. MAZUMDER S, Bindu S, De R, Debsharma S, et al
    Emerging role of mitochondrial DAMPs, aberrant mitochondrial dynamics and anomalous mitophagy in gut mucosal pathogenesis.
    Life Sci. 2022 Jul 1:120753. doi: 10.1016/j.lfs.2022.120753.
    PubMed     Abstract available
    
    
    
29. PANDA M, Kalita E, Singh S, Kumar K, et al
    MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.
    Life Sci. 2022 Jul 1:120761. doi: 10.1016/j.lfs.2022.120761.
    PubMed     Abstract available
    
    
    June 2022
30. GUPTA A, Jayakumar MN, Saleh MA, Kannan M, et al
    SARS-CoV-2-infection induced growth factors play differential roles in COVID-19 pathogenesis.
    Life Sci. 2022 Jun 11:120703. doi: 10.1016/j.lfs.2022.120703.
    PubMed     Abstract available
    
    
    May 2022
31. PATIL PJ, Sutar SS, Usman M, Patil DN, et al
    Exploring bioactive peptides as potential therapeutic and biotechnology treasures: A contemporary perspective.
    Life Sci. 2022;301:120637.
    PubMed     Abstract available
    
    
    
32. FERNANDES MF, Chan JZ, Hung CCJ, Tomczewski MV, et al
    Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein.
    Life Sci. 2022;301:120624.
    PubMed     Abstract available
    
    
    
33. HUANG DY, Wang GM, Ke ZR, Zhou Y, et al
    Megakaryocytes in pulmonary diseases.
    Life Sci. 2022 May 1:120602. doi: 10.1016/j.lfs.2022.120602.
    PubMed     Abstract available
    
    
    April 2022
34. YOUNG LJ, Antwi-Boasiako S, Ferrall J, Wold LE, et al
    Genetic and non-genetic risk factors associated with atrial fibrillation.
    Life Sci. 2022;299:120529.
    PubMed     Abstract available
    
    
    March 2022
35. MAZIDIMORADI A, Alemzadeh E, Alemzadeh E, Salehiniya H, et al
    The effect of polyunsaturated fatty acids on the severity and mortality of COVID patients: A systematic review.
    Life Sci. 2022 Mar 28:120489. doi: 10.1016/j.lfs.2022.120489.
    PubMed     Abstract available
    
    
    
36. NADEALI Z, Rezaei FM, Aria H, Nikpour P, et al
    Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.
    Life Sci. 2022 Mar 11:120482. doi: 10.1016/j.lfs.2022.120482.
    PubMed     Abstract available
    
    
    
37. MENENDEZ SG, Martin Gimenez VM, Holick MF, Barrantes FJ, et al
    COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent.
    Life Sci. 2022;297:120464.
    PubMed     Abstract available
    
    
    February 2022
38. BHATT AN, Kumar A, Rai Y, Kumari N, et al
    Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.
    Life Sci. 2022;295:120411.
    PubMed     Abstract available
    
    
    
39. SAGHAFI N, Rezaee SA, Momtazi-Borojeni AA, Tavasolian F, et al
    The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19.
    Life Sci. 2022;294:120392.
    PubMed     Abstract available
    
    
    January 2022
40. TAN DX, Reiter RJ
    Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality.
    Life Sci. 2022 Jan 30:120368. doi: 10.1016/j.lfs.2022.120368.
    PubMed     Abstract available
    
    
    
41. PORTALES AE, Mustafa ER, McCarthy CI, Cornejo MP, et al
    ACE2 internalization induced by a SARS-CoV-2 recombinant protein is modulated by angiotensin II type 1 and bradykinin 2 receptors.
    Life Sci. 2022;293:120284.
    PubMed     Abstract available
    
    
    
42. SILVA MG, Falcoff NL, Corradi GR, Alfie J, et al
    Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytes.
    Life Sci. 2022 Jan 12:120324. doi: 10.1016/j.lfs.2022.120324.
    PubMed     Abstract available
    
    
    December 2021
43. ZAKI MO, Elsherbiny DA, Salama M, Azab SS, et al
    Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy.
    Life Sci. 2021 Dec 30:120267. doi: 10.1016/j.lfs.2021.120267.
    PubMed     Abstract available
    
    
    October 2021
44. ULASOV AV, Rosenkranz AA, Georgiev GP, Sobolev AS, et al
    Nrf2/Keap1/ARE signaling: Towards specific regulation.
    Life Sci. 2021 Oct 31:120111. doi: 10.1016/j.lfs.2021.120111.
    PubMed     Abstract available
    
    
    
45. AHMAD S, Hatmal MM, Lambuk L, Al-Hatamleh MAI, et al
    The role of TNFR2(+) Tregs in COVID-19: An overview and a potential therapeutic strategy.
    Life Sci. 2021;286:120063.
    PubMed     Abstract available
    
    
    August 2021
46. LUTHRA R, Kaur S, Bhandari K
    Applications of CRISPR as a potential therapeutic.
    Life Sci. 2021 Aug 25:119908. doi: 10.1016/j.lfs.2021.119908.
    PubMed     Abstract available
    
    
    
47. PAL D, Goyal J, Sharma U, Sharma A, et al
    Mesenchymal stem cells in SARS-CoV-2 infection: A hype or hope.
    Life Sci. 2021;284:119901.
    PubMed     Abstract available
    
    
    
48. AMRUTA N, Engler-Chiurazzi EB, Murray-Brown IC, Gressett TE, et al
    In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice.
    Life Sci. 2021;284:119881.
    PubMed     Abstract available
    
    
    June 2021
49. ADITYA RAO SJ, Shetty NP
    Evolutionary selectivity of amino acid is inspired from the enhanced structural stability and flexibility of the folded protein.
    Life Sci. 2021 Jun 28:119774. doi: 10.1016/j.lfs.2021.119774.
    PubMed     Abstract available
    
    
    
50. CHAN Y, Ng SW, Singh SK, Gulati M, et al
    Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.
    Life Sci. 2021;280:119744.
    PubMed     Abstract available
    
    
    
51. LEE MC, Chen YK, Tsai-Wu JJ, Hsu YJ, et al
    Zinc supplementation augments the suppressive effects of repurposed NF-kappaB inhibitors on ACE2 expression in human lung cell lines.
    Life Sci. 2021;280:119752.
    PubMed     Abstract available
    
    
    May 2021
52. KARSLI E, Sabirli R, Altintas E, Canacik O, et al
    Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study.
    Life Sci. 2021 May 17:119634. doi: 10.1016/j.lfs.2021.119634.
    PubMed     Abstract available
    
    
    
53. CHATTERJEE S, Mishra S, Chowdhury KD, Ghosh CK, et al
    Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view.
    Life Sci. 2021 May 12:119580. doi: 10.1016/j.lfs.2021.119580.
    PubMed     Abstract available
    
    
    
54. OKUYAN HM, Dogan S, Bal T, Cabalak M, et al
    Beclin-1, an autophagy-related protein, is associated with the disease severity of COVID-19.
    Life Sci. 2021 May 10:119596. doi: 10.1016/j.lfs.2021.119596.
    PubMed     Abstract available
    
    
    April 2021
55. DAWRE S, Maru S
    Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment.
    Life Sci. 2021 Apr 26:119561. doi: 10.1016/j.lfs.2021.119561.
    PubMed     Abstract available
    
    
    
56. GHAEBI M, Tahmasebi S, Jozghorbani M, Sadeghi A, et al
    Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2.
    Life Sci. 2021;277:119503.
    PubMed     Abstract available
    
    
    
57. CHEUDJEU A
    Antiviral strategies should focus on stimulating the biosynthesis of heparan sulfates, not their inhibition.
    Life Sci. 2021;277:119508.
    PubMed     Abstract available
    
    
    
58. PARIS GC, de A Azevedo A, Ferreira AL, de A Azevedo YM, et al
    Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19.
    Life Sci. 2021 Apr 15:119510. doi: 10.1016/j.lfs.2021.119510.
    PubMed     Abstract available
    
    
    March 2021
59. TAHMASEBI S, Saeed BQ, Temirgalieva E, Yumashev AV, et al
    Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.
    Life Sci. 2021 Mar 28:119437. doi: 10.1016/j.lfs.2021.119437.
    PubMed     Abstract available
    
    
    
60. PRASANNA P, Rathee S, Upadhyay A, Sulakshana S, et al
    Nanotherapeutics in the treatment of acute respiratory distress syndrome.
    Life Sci. 2021;276:119428.
    PubMed     Abstract available
    
    
    
61. POTJE SR, Costa TJ, Fraga-Silva TFC, Martins RB, et al
    Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients.
    Life Sci. 2021;276:119376.
    PubMed     Abstract available
    
    
    
62. POSADAS-SANCHEZ R, Sanchez-Munoz F, Guzman-Martin CA, Hernandez-Diaz Couder A, et al
    Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity.
    Life Sci. 2021;276:119410.
    PubMed     Abstract available
    
    
    
63. CHENG X, Xin S, Chen Y, Li L, et al
    Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study.
    Life Sci. 2021;275:119371.
    PubMed     Abstract available
    
    
    
64. DIMBATH E, Maddipati V, Stahl J, Sewell K, et al
    Implications of microscale lung damage for COVID-19 pulmonary ventilation dynamics: A narrative review.
    Life Sci. 2021;274:119341.
    PubMed     Abstract available
    
    
    
65. HASSANZADEH P
    The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing.
    Life Sci. 2021 Mar 4:119289. doi: 10.1016/j.lfs.2021.119289.
    PubMed     Abstract available
    
    
    February 2021
66. CHIAPPALUPI S, Salvadori L, Vukasinovic A, Donato R, et al
    Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.
    Life Sci. 2021 Feb 23:119251. doi: 10.1016/j.lfs.2021.119251.
    PubMed     Abstract available
    
    
    
67. SANTIESTEBAN-LORES LE, Amamura TA, da Silva TF, Midon LM, et al
    A double edged-sword - The Complement System during SARS-CoV-2 infection.
    Life Sci. 2021;272:119245.
    PubMed     Abstract available
    
    
    
68. KUNNUMAKKARA AB, Rana V, Parama D, Banik K, et al
    COVID-19, cytokines, inflammation, and spices: How are they related?
    Life Sci. 2021 Feb 16:119201. doi: 10.1016/j.lfs.2021.119201.
    PubMed     Abstract available
    
    
    
69. SAVIRON-CORNUDELLA R, Villalba A, Esteban LM, Tajada M, et al
    Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing.
    Life Sci. 2021 Feb 9:119200. doi: 10.1016/j.lfs.2021.119200.
    PubMed     Abstract available
    
    
    January 2021
70. AGHBASH PS, Eslami N, Shamekh A, Entezari-Maleki T, et al
    SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis.
    Life Sci. 2021;270:119124.
    PubMed     Abstract available
    
    
    
71. WANG SC, Wang YF
    Cardiovascular protective properties of oxytocin against COVID-19.
    Life Sci. 2021 Jan 26:119130. doi: 10.1016/j.lfs.2021.119130.
    PubMed     Abstract available
    
    
    
72. ABID SA, Suhail A, Al-Kadmy IMS, Sattar AA, et al
    Biosensors as a future diagnostic approach for COVID-19.
    Life Sci. 2021 Jan 25:119117. doi: 10.1016/j.lfs.2021.119117.
    PubMed     Abstract available
    
    
    
73. MANSOUR BS, Salem NA, Kader GA, Abdel-Alrahman G, et al
    Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model.
    Life Sci. 2021;269:119099.
    PubMed     Abstract available
    
    
    
74. FAWAD M, Mubarik S, Malik SS, Ren J, et al
    Statistical analysis of COVID-19 infection caused by environmental factors: Evidence from Pakistan.
    Life Sci. 2021 Jan 18:119093. doi: 10.1016/j.lfs.2021.119093.
    PubMed     Abstract available
    
    
    
75. MEIDANINIKJEH S, Sabouni N, Marzouni HZ, Bengar S, et al
    Monocytes and macrophages in COVID-19: Friends and foes.
    Life Sci. 2021;269:119010.
    PubMed     Abstract available
    
    
    
76. HAROUN RA, Osman WH, Eessa AM
    Interferon-gamma-induced protein 10 (IP-10) and serum amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity.
    Life Sci. 2021 Jan 14:119019. doi: 10.1016/j.lfs.2021.119019.
    PubMed     Abstract available
    
    
    
77. ZHANG Z, Wang T, Liu F, Zhu A, et al
    The proteomic characteristics of airway mucus from critical ill COVID-19 patients.
    Life Sci. 2021;269:119046.
    PubMed     Abstract available
    
    
    December 2020
78. KOTNALA S, Dhasmana A, Kashyap VK, Chauhan SC, et al
    A bird eye view on cystic fibrosis: An underestimated multifaceted chronic disorder.
    Life Sci. 2020 Dec 28:118959. doi: 10.1016/j.lfs.2020.118959.
    PubMed     Abstract available
    
    
    
79. HIRAWAT R, Saifi MA, Godugu C
    Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.
    Life Sci. 2020;267:118923.
    PubMed     Abstract available
    
    
    
80. SILVEIRA MM, Moreira GMSG, Mendonca M
    DNA vaccines against COVID-19: Perspectives and challenges.
    Life Sci. 2020 Dec 19:118919. doi: 10.1016/j.lfs.2020.118919.
    PubMed     Abstract available
    
    
    
81. P KM, Sivashanmugam K, Kandasamy M, Subbiah R, et al
    Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-beta signalling in COVID-19 survivors.
    Life Sci. 2020;266:118883.
    PubMed     Abstract available
    
    
    
82. LU J, Hou Y, Ge S, Wang X, et al
    Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
    Life Sci. 2020;266:118889.
    PubMed     Abstract available
    
    
    November 2020
83. LA MARCA G, Barp J, Frenos S, Mugelli A, et al
    Thermal inactivation of SARS COVID-2 virus: Are steam inhalations a potential treatment?
    Life Sci. 2020 Nov 21:118801. doi: 10.1016/j.lfs.2020.118801.
    PubMed     Abstract available
    
    
    
84. SABIRLI R, Koseler A, Goren T, Turkcuer I, et al
    High GRP78 levels in Covid-19 infection: A case-control study.
    Life Sci. 2020 Nov 18:118781. doi: 10.1016/j.lfs.2020.118781.
    PubMed     Abstract available
    
    
    
85. LANG Y, Chen K, Li Z, Li H, et al
    The nucleocapsid protein of zoonotic betacoronaviruses is an attractive target for antiviral drug discovery.
    Life Sci. 2020 Nov 12:118754. doi: 10.1016/j.lfs.2020.118754.
    PubMed     Abstract available
    
    
    October 2020
86. DHAUNDIYAL A, Kumari P, Jawalekar SS, Chauhan G, et al
    Is highly expressed ACE 2 in pregnant women "a curse" in times of COVID-19 pandemic?
    Life Sci. 2020 Oct 28:118676. doi: 10.1016/j.lfs.2020.118676.
    PubMed     Abstract available
    
    
    
87. SHRESTHA DB, Budhathoki P, Syed NI, Rawal E, et al
    Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.
    Life Sci. 2020 Oct 26:118663. doi: 10.1016/j.lfs.2020.118663.
    PubMed     Abstract available
    
    
    
88. BAKADIA BM, Boni BOO, Ahmed AAQ, Yang G, et al
    The impact of oxidative stress damage induced by the environmental stressors on COVID-19.
    Life Sci. 2020 Oct 26:118653. doi: 10.1016/j.lfs.2020.118653.
    PubMed     Abstract available
    
    
    
89. PAN ZY, Chang YX, Han N, Hou FY, et al
    Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice.
    Life Sci. 2020 Oct 22:118450. doi: 10.1016/j.lfs.2020.118450.
    PubMed     Abstract available
    
    
    
90. MORRIS G, Bortolasci CC, Puri BK, Olive L, et al
    Preventing the development of severe CoVID 19 by modifying immunothrombosis.
    Life Sci. 2020 Oct 20:118617. doi: 10.1016/j.lfs.2020.118617.
    PubMed     Abstract available
    
    
    
91. BAILLY C, Vergoten G
    Mechanistic insights into dimethyl cardamonin-mediated pharmacological effects: A double control of the AMPK-HMGB1 signaling axis.
    Life Sci. 2020 Oct 18:118601. doi: 10.1016/j.lfs.2020.118601.
    PubMed     Abstract available
    
    
    
92. YADAV P, Vats R, Bano A, Bhardwaj R, et al
    Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.
    Life Sci. 2020;263:118588.
    PubMed     Abstract available
    
    
    
93. SATARKER S, Nampoothiri M
    Involvement of the nervous system in COVID-19: The bell should toll in the brain.
    Life Sci. 2020 Oct 6:118568. doi: 10.1016/j.lfs.2020.118568.
    PubMed     Abstract available
    
    
    
94. MORRIS G, Athan E, Walder K, Bortolasci CC, et al
    Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
    Life Sci. 2020;262:118541.
    PubMed     Abstract available
    
    
    September 2020
95. VITIELLO A, Ferrara F
    Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19.
    Life Sci. 2020;262:118510.
    PubMed     Abstract available
    
    
    
96. PENG W, Wu H, Tan Y, Li M, et al
    Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019.
    Life Sci. 2020;262:118496.
    PubMed     Abstract available
    
    
    
97. SADEGHI S, Soudi S, Shafiee A, Hashemi SM, et al
    Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action.
    Life Sci. 2020;262:118493.
    PubMed     Abstract available
    
    
    
98. UNUDURTHI SD, Luthra P, Bose RJC, McCarthy J, et al
    Cardiac inflammation in COVID-19: Lessons from heart failure.
    Life Sci. 2020 Sep 21:118482. doi: 10.1016/j.lfs.2020.118482.
    PubMed     Abstract available
    
    
    
99. BELHASSAN A, En-Nahli F, Zaki H, Lakhlifi T, et al
    Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach.
    Life Sci. 2020 Sep 18:118469. doi: 10.1016/j.lfs.2020.118469.
    PubMed     Abstract available
    
    
    
100. VINAYAGAM S, Sattu K
     SARS-CoV-2 and coagulation disorders in different organs.
     Life Sci. 2020;260:118431.
     PubMed     Abstract available
     
     
     
101. KHATRI R, Gupta RK, Vats P, Bansal V, et al
     Subclinical elevated B-type Natriuretic Peptide (BNP) indicates endothelial dysfunction contributing to hypoxia susceptibility in healthy individuals.
     Life Sci. 2020 Sep 11:118408. doi: 10.1016/j.lfs.2020.118408.
     PubMed     Abstract available
     
     
     
102. CHAUDHRY SN, Hazafa A, Mumtaz M, Kalsoom U, et al
     New insight on possible vaccine development against SARS-CoV-2.
     Life Sci. 2020 Sep 11:118421. doi: 10.1016/j.lfs.2020.118421.
     PubMed     Abstract available
     
     
     
103. DUERR GD, Heine A, Hamiko M, Zimmer S, et al
     Parameters predicting COVID-19-induced myocardial injury and mortality.
     Life Sci. 2020 Sep 9:118400. doi: 10.1016/j.lfs.2020.118400.
     PubMed     Abstract available
     
     
     August 2020
104. CACCIAPUOTI S, De Rosa A, Gelzo M, Megna M, et al
     Immunocytometric analysis of COVID patients: A contribution to personalized therapy?
     Life Sci. 2020 Aug 29:118355. doi: 10.1016/j.lfs.2020.118355.
     PubMed     Abstract available
     
     
     
105. CHEUDJEU A
     Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19.
     Life Sci. 2020;260:118335.
     PubMed     Abstract available
     
     
     
106. WANG F, Zheng S, Zheng C, Sun X, et al
     Attaching clinical significance to COVID-19-associated diarrhea.
     Life Sci. 2020;260:118312.
     PubMed     Abstract available
     
     
     
107. BHAVANA V, Thakor P, Singh SB, Mehra NK, et al
     COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.
     Life Sci. 2020 Aug 23:118336. doi: 10.1016/j.lfs.2020.118336.
     PubMed     Abstract available
     
     
     
108. ELFIKY AA, Baghdady AM, Ali SA, Ahmed MI, et al
     GRP78 targeting: Hitting two birds with a stone.
     Life Sci. 2020 Aug 22:118317. doi: 10.1016/j.lfs.2020.118317.
     PubMed     Abstract available
     
     
     
109. VARGAS-ALARCON G, Posadas-Sanchez R, Ramirez-Bello J
     Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies.
     Life Sci. 2020;260:118313.
     PubMed     Abstract available
     
     
     
110. PARVATHANENI V, Gupta V
     Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.
     Life Sci. 2020 Aug 17:118275. doi: 10.1016/j.lfs.2020.118275.
     PubMed     Abstract available
     
     
     
111. HOSSEINI FS, Amanlou M
     Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
     Life Sci. 2020;258:118205.
     PubMed     Abstract available
     
     
     
112. MAHENDIRATTA S, Batra G, Sarma P, Kumar H, et al
     Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review.
     Life Sci. 2020;258:118207.
     PubMed     Abstract available
     
     
     
113. MOHAMMAD A, Marafie SK, Alshawaf E, Abu-Farha M, et al
     Structural analysis of ACE2 variant N720D demonstrates a higher binding affinity to TMPRSS2.
     Life Sci. 2020 Aug 5:118219. doi: 10.1016/j.lfs.2020.118219.
     PubMed     Abstract available
     
     
     
114. DAS S, Anu KR, Birangal SR, Nikam AN, et al
     Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review.
     Life Sci. 2020 Aug 3:118202. doi: 10.1016/j.lfs.2020.118202.
     PubMed     Abstract available
     
     
     
115. MANSOURABADI AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N, et al
     The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
     Life Sci. 2020 Aug 1:118185. doi: 10.1016/j.lfs.2020.118185.
     PubMed     Abstract available
     
     
     July 2020
116. MORRIS G, Bortolasci CC, Puri BK, Olive L, et al
     The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach.
     Life Sci. 2020 Jul 30:118166. doi: 10.1016/j.lfs.2020.118166.
     PubMed     Abstract available
     
     
     
117. SHARMA K, Morla S, Goyal A, Kumar S, et al
     Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2.
     Life Sci. 2020 Jul 29:118169. doi: 10.1016/j.lfs.2020.118169.
     PubMed     Abstract available
     
     
     
118. AKBARI H, Tabrizi R, Lankarani KB, Aria H, et al
     The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
     Life Sci. 2020 Jul 28:118167. doi: 10.1016/j.lfs.2020.118167.
     PubMed     Abstract available
     
     
     
119. SUT BB
     Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13.
     Life Sci. 2020 Jul 28:118170. doi: 10.1016/j.lfs.2020.118170.
     PubMed     Abstract available
     
     
     
120. ZHANG J, Wang M, Ding W, Wan J, et al
     The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
     Life Sci. 2020;257:118142.
     PubMed     Abstract available
     
     
     
121. PANIRI A, Akhavan-Niaki H
     Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
     Life Sci. 2020 Jul 18:118114. doi: 10.1016/j.lfs.2020.118114.
     PubMed     Abstract available
     
     
     
122. ZUCKERBERG J, Shaik M, Nelin TD, Widmeier K, et al
     A lung for all: Novel mechanical ventilator for emergency and low-resource settings.
     Life Sci. 2020 Jul 17:118113. doi: 10.1016/j.lfs.2020.118113.
     PubMed     Abstract available
     
     
     
123. JAFARZADEH A, Chauhan P, Saha B, Jafarzadeh S, et al
     Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
     Life Sci. 2020 Jul 17:118102. doi: 10.1016/j.lfs.2020.118102.
     PubMed     Abstract available
     
     
     
124. JAMWAL S, Gautam A, Elsworth J, Kumar M, et al
     An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic.
     Life Sci. 2020 Jul 17:118105. doi: 10.1016/j.lfs.2020.118105.
     PubMed     Abstract available
     
     
     
125. ABBASIFARD M, Khorramdelazad H
     The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.
     Life Sci. 2020;257:118097.
     PubMed     Abstract available
     
     
     
126. HAZRA S, Chaudhuri AG, Tiwary BK, Chakrabarti N, et al
     Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
     Life Sci. 2020 Jul 14:118096. doi: 10.1016/j.lfs.2020.118096.
     PubMed     Abstract available
     
     
     
127. ABDIN SM, Elgendy SM, Alyammahi SK, Alhamad DW, et al
     Tackling the cytokine storm in COVID-19, challenges, and hopes.
     Life Sci. 2020 Jul 11:118054. doi: 10.1016/j.lfs.2020.118054.
     PubMed     Abstract available
     
     
     
128. BEHL T, Kaur I, Bungau S, Kumar A, et al
     The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions.
     Life Sci. 2020;257:118075.
     PubMed     Abstract available
     
     
     
129. BHARADWAJ S, Lee KE, Dwivedi VD, Kang SG, et al
     Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations.
     Life Sci. 2020;257:118080.
     PubMed     Abstract available
     
     
     
130. HAJIVALILI M, Hosseini M, Haji-Fatahaliha M
     Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges.
     Life Sci. 2020 Jul 9:118058. doi: 10.1016/j.lfs.2020.118058.
     PubMed     Abstract available
     
     
     
131. YAVARPOUR-BALI H, Ghasemi-Kasman M
     Update on neurological manifestations of COVID-19.
     Life Sci. 2020 Jul 8:118063. doi: 10.1016/j.lfs.2020.118063.
     PubMed     Abstract available
     
     
     
132. STERNBERG A, Naujokat C
     Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination.
     Life Sci. 2020 Jul 6:118056. doi: 10.1016/j.lfs.2020.118056.
     PubMed     Abstract available
     
     
     June 2020
133. BENITEZ-CARDOZA CG, Vique-Sanchez JL
     Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.
     Life Sci. 2020;256:117970.
     PubMed     Abstract available
     
     
     
134. PANDEY SC, Pande V, Sati D, Upreti S, et al
     Vaccination strategies to combat novel corona virus SARS-CoV-2.
     Life Sci. 2020;256:117956.
     PubMed     Abstract available
     
     
     
135. HAGE-MELIM LIDS, Federico LB, de Oliveira NKS, Francisco VCC, et al
     Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
     Life Sci. 2020;256:117963.
     PubMed     Abstract available
     
     
     
136. BANU N, Panikar SS, Leal LR, Leal AR, et al
     Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.
     Life Sci. 2020;256:117905.
     PubMed     Abstract available
     
     
     
137. SIMKO F, Reiter RJ
     Is melatonin deficiency a unifying pathomechanism of high risk patients with COVID-19?
     Life Sci. 2020;256:117902.
     PubMed    
     
     
     
138. KHODIR AE, Samra YA, Said E
     A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.
     Life Sci. 2020 Jun 3:117907. doi: 10.1016/j.lfs.2020.117907.
     PubMed     Abstract available
     
     
     
139. YAZDANPANAH F, Hamblin MR, Rezaei N
     The immune system and COVID-19: Friend or foe?
     Life Sci. 2020 Jun 2:117900. doi: 10.1016/j.lfs.2020.117900.
     PubMed     Abstract available
     
     
     
140. PANDEY A, Nikam AN, Shreya AB, Mutalik SP, et al
     Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
     Life Sci. 2020 Jun 1:117883. doi: 10.1016/j.lfs.2020.117883.
     PubMed     Abstract available
     
     
     May 2020
141. BANERJEE A, Czinn SJ, Reiter RJ, Blanchard TG, et al
     Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
     Life Sci. 2020;255:117842.
     PubMed     Abstract available
     
     
     
142. TONG PB, Lin LY, Tran TH
     Coronaviruses pandemics: Can neutralizing antibodies help?
     Life Sci. 2020 May 22:117836. doi: 10.1016/j.lfs.2020.117836.
     PubMed     Abstract available
     
     
     
143. GURUNG AB, Ali MA, Lee J, Farah MA, et al
     Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.
     Life Sci. 2020;255:117831.
     PubMed     Abstract available
     
     
     
144. RENU K, Prasanna PL, Valsala Gopalakrishnan A
     Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.
     Life Sci. 2020;255:117839.
     PubMed     Abstract available
     
     
     
145. MARTIN GIMENEZ VM, Inserra F, Tajer CD, Mariani J, et al
     Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.
     Life Sci. 2020;254:117808.
     PubMed     Abstract available
     
     
     
146. KERMALI M, Khalsa RK, Pillai K, Ismail Z, et al
     The role of biomarkers in diagnosis of COVID-19 - A systematic review.
     Life Sci. 2020 May 13:117788. doi: 10.1016/j.lfs.2020.117788.
     PubMed     Abstract available
     
     
     
147. KERMALI M, Khalsa RK, Pillai K, Ismail Z, et al
     The role of biomarkers in diagnosis of COVID-19 - A systematic review.
     Life Sci. 2020;254:117788.
     PubMed     Abstract available
     
     
     
148. PATIL VM, Singhal S, Masand N
     A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
     Life Sci. 2020;254:117775.
     PubMed     Abstract available
     
     
     
149. POOLADANDA V, Thatikonda S, Godugu C
     The current understanding and potential therapeutic options to combat COVID-19.
     Life Sci. 2020 May 8:117765. doi: 10.1016/j.lfs.2020.117765.
     PubMed     Abstract available
     
     
     April 2020
150. HERRERA EA, Gonzalez-Candia A
     Comment on Melatonin as a potential adjuvant treatment for COVID-19.
     Life Sci. 2020 Apr 30:117739. doi: 10.1016/j.lfs.2020.117739.
     PubMed    
     
     
     
151. BABAPOOR-FARROKHRAN S, Gill D, Walker J, Rasekhi RT, et al
     Myocardial injury and COVID-19: Possible mechanisms.
     Life Sci. 2020;253:117723.
     PubMed     Abstract available
     
     
     
152. SALLES C
     Correspondence COVID-19: Melatonin as a potential adjuvant treatment.
     Life Sci. 2020 Apr 22:117716. doi: 10.1016/j.lfs.2020.117716.
     PubMed    
     
     
     
153. SHAH B, Modi P, Sagar SR
     In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.
     Life Sci. 2020 Apr 9:117652. doi: 10.1016/j.lfs.2020.117652.
     PubMed     Abstract available
     
     
     March 2020
154. ELFIKY AA
     Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
     Life Sci. 2020 Mar 25:117592. doi: 10.1016/j.lfs.2020.117592.
     PubMed     Abstract available
     
     
     February 2020
155. ELFIKY AA
     Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
     Life Sci. 2020 Feb 28:117477. doi: 10.1016/j.lfs.2020.117477.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge.